Key Focus:
CANCER
RESEARCH

Reimagining Cancer Discovery Through Genomics

Cancer research is entering a new era defined by molecular precision, not morphology. Genomics has become the cornerstone of modern oncology, enabling researchers to decode the complex landscape of mutations, expression patterns, and epigenetic changes that drive tumor initiation, progression, and resistance.

At AUGenomics, we help oncology researchers uncover these molecular signatures with next-generation sequencing (NGS), liquid biopsy profiling, and multi-omic integration. Whether your focus is tumor evolution, immune response, or therapeutic resistance, our sequencing solutions empower you to explore cancer biology at single-base resolution.

Cancer is not a single disease but a dynamic ecosystem of genomic alterations. Through advanced sequencing and bioinformatics, scientists can now identify driver mutations, characterize tumor heterogeneity, and trace clonal evolution across time and treatment. From discovery research to translational studies, genomics reveals the underlying mechanisms that make personalized cancer therapy possible.

Comprehensive mutation profiling (SNVs, indels, CNVs, fusions)

Identification of novel oncogenic drivers in tumor subtypes

Transcriptomic analysis to map tumor microenvironment or immune response

Methylation and epigenetic signature discovery for classification and risk stratification

Longitudinal tracking of clonal evolution and resistance via liquid biopsy

Development and validation of companion diagnostics

Multi-omic integration for predictive modeling of therapy response

Why Genomics is Transforming Cancer Research

Every tumor carries a unique genetic signature. Genomic sequencing provides a comprehensive view of these changes, from point mutations and copy number variations to fusion transcripts and methylation patterns. This molecular data informs:

Tumor classification and molecular subtyping
Biomarker identification for prognosis and therapy selection
Drug target discovery and resistance mechanism mapping
Real-time monitoring of tumor burden via circulating DNA (liquid biopsy)

At AUGenomics, we combine high-resolution sequencing with AI-assisted variant interpretation and multi-omic integration to deliver insights that accelerate discovery. Our methods capture both known oncogenic drivers and novel alterations—helping you uncover mechanisms that traditional panels might overlook.

Machine learning and advanced bioinformatics amplify the power of genomics by revealing hidden associations between mutations, immune signaling, and therapeutic response—fueling more predictive, data-driven oncology research.

Common Sample Types

We support a wide range of tumor and biofluid samples used in cancer research, including:

FFPE tumor tissue — archived clinical samples for retrospective studies
Fresh-frozen tumor tissue — optimal for high-quality RNA and DNA sequencing
cfDNA / ctDNA (plasma, serum) — liquid biopsy for non-invasive tumor profiling
Whole blood / PBMCs — immune monitoring and host response studies
Organoids / patient-derived xenografts (PDX) — preclinical model characterization
Bone marrow aspirates — hematologic malignancy profiling
Cerebrospinal fluid (CSF) — central nervous system tumor detection
Ascites or pleural fluid — metastatic tumor sampling

Tailored Solutions

AUGenomics supports cancer research at every stage—from discovery to validation.

Oncology Biomarker Discovery: Identify prognostic and predictive biomarkers across tumor cohorts.
Precision Oncology: Characterize patient-specific mutations for targeted therapy development.
Immuno-Oncology: Sequence immune repertoires and identify neoantigens or TCR signatures.
Liquid Biopsy: Detect and monitor circulating tumor DNA (ctDNA) for early detection and MRD tracking.
Cancer Epigenomics: Profile methylation and chromatin accessibility to uncover regulatory mechanisms.
Drug Discovery & Development: Evaluate off-target effects, pharmacogenomic markers, and treatment efficacy.

Explore our specialized sequencing solutions for cancer research:

Whole Genome Sequencing (WGS) · Whole Exome Sequencing (WES) · RNA Sequencing · cfDNA Sequencing · Single-Cell RNA-seq · Methylation Profiling

Why Us?

At AUGenomics, we don’t just process samples, we partner in discovery. Our team of genomic scientists, method developers, and bioinformaticians provide hands-on collaboration and tailored experimental design to help you generate publishable, actionable data.

We deliver:

Customized workflows for challenging tumor samples and low-input cfDNA
Ultra-fast turnaround (as little as 3–5 days for select services)
Transparent project tracking via our online portal
Superior data quality validated against industry standards
Cross-disciplinary expertise spanning oncology, immunology, and molecular diagnostics
Collaborative support from scientists who understand translational cancer research